Developing
breakthrough
AXL therapeutics
to improve
patients’ lives
Summary of
Annual Report
2021
Highlights 2021
Our Vision
BerGenBio (OSE:BGBIO) is a clinical stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
Initiated new lung
cancer STK11
program
Treated >600
patients to date
with bemcentinib
Maturing AML data
Fast track designations received
Focused bemcentinib strategy established
Initiated Phase IB tilvestamab trial
Clinical efficacy seen in COVID-19
Treated >600
patients to date
with bemcentinib
I am optimistic about our ability to continue building BerGenBio, creating value for our shareholders while conducting our business in line with our responsibilities as a good corporate citizen.
Anders Tullgren
Chair
Since joining BerGenBio, we have refined our strategy to optimize the development pathway for our lead compound bemcentinib and have prioritized the development of this promising candidate in lung cancer and severe respiratory illnesses.
Martin Olin
Chief Executive Officer
BerGenBio has built the world’s-leading understanding of the tyrosine kinase target AXL and is uniquely positioned to explore potential clinical applications of its selective AXL inhibitors bemcentinib and tilvestimab.
The tyrosine kinase AXL is upregulated in aggressive diseases including cancer and severe respiratory infections and plays a key role in both the innate and adaptive immune system.
BerGenBio has established a network of prestigious collaborators and uses advanced technologies to enable the exploration of multiple potential applications of its selective AXL inhibitors.
Environmental, Social and Governance
We use the term Environment, Social and Governance (ESG) to describe our commitments as a responsible corporate citizen, and we fully support the United Nations’ Sustainable Development Goals (SDGs) and Agenda 2030. Over the last two years we have strengthen our sustainability management which will continue in the coming years.
